1. Home
  2. RPGL vs SCYX Comparison

RPGL vs SCYX Comparison

Compare RPGL & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RPGL

Republic Power Group Limited Class A Ordinary Shares

N/A

Current Price

$0.32

Market Cap

74.0M

Sector

Technology

ML Signal

N/A

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.74

Market Cap

60.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RPGL
SCYX
Founded
2015
1999
Country
Singapore
United States
Employees
8
29
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.0M
60.4M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
RPGL
SCYX
Price
$0.32
$0.74
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
12.0M
360.2K
Earning Date
05-16-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.36
EPS
N/A
N/A
Revenue
N/A
$257,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$608.78
P/E Ratio
$21.40
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$0.57
52 Week High
$8.44
$1.29

Technical Indicators

Market Signals
Indicator
RPGL
SCYX
Relative Strength Index (RSI) 41.90 30.60
Support Level $0.32 $0.69
Resistance Level $0.71 $0.89
Average True Range (ATR) 0.52 0.06
MACD -0.14 -0.03
Stochastic Oscillator 2.57 4.25

Price Performance

Historical Comparison
RPGL
SCYX

About RPGL Republic Power Group Limited Class A Ordinary Shares

Republic Power Group Ltd is a provider of customized ERP software solutions, consulting and technical support services, and peripheral hardware to corporate clients and government agencies, including airports, cruise terminals, and technology, trading, and logistics companies. The Company operates from Singapore and has historically served clients in Singapore and Malaysia, offering ERP systems with functions such as accounting, procurement, workflow automation, real-time monitoring, and capabilities including planning, surveillance, and threat detection. The Company leverages artificial intelligence and modular algorithms to address complex operational requirements and integrates sensors, controls, and other hardware to enable IoT connectivity with autonomous or semiautonomous outcomes.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: